2,431 Shares in Waters Corporation $WAT Acquired by Guyasuta Investment Advisors Inc.

Guyasuta Investment Advisors Inc. bought a new position in Waters Corporation (NYSE:WAT) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,431 shares of the medical instruments supplier’s stock, valued at approximately $724,000.

Other institutional investors also recently bought and sold shares of the company. Fundsmith LLP boosted its holdings in shares of Waters by 9.6% during the third quarter. Fundsmith LLP now owns 3,955,498 shares of the medical instruments supplier’s stock worth $1,185,898,000 after purchasing an additional 347,091 shares during the last quarter. Geode Capital Management LLC increased its stake in Waters by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,593,388 shares of the medical instruments supplier’s stock valued at $602,921,000 after purchasing an additional 8,590 shares during the last quarter. Invesco Ltd. lifted its position in Waters by 32.3% during the third quarter. Invesco Ltd. now owns 1,472,419 shares of the medical instruments supplier’s stock worth $441,446,000 after buying an additional 359,596 shares during the period. Fundsmith Investment Services LTD. lifted its position in Waters by 11.1% during the third quarter. Fundsmith Investment Services LTD. now owns 1,356,289 shares of the medical instruments supplier’s stock worth $406,629,000 after buying an additional 135,504 shares during the period. Finally, Veritas Asset Management LLP boosted its stake in Waters by 112.3% in the 4th quarter. Veritas Asset Management LLP now owns 1,241,206 shares of the medical instruments supplier’s stock worth $471,447,000 after buying an additional 656,436 shares during the last quarter. 94.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on WAT. Piper Sandler assumed coverage on Waters in a report on Thursday, June 11th. They issued a “neutral” rating and a $400.00 price target for the company. HSBC increased their price objective on shares of Waters from $415.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, June 3rd. Bank of America raised their target price on shares of Waters from $370.00 to $400.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 2nd. Barclays upped their price target on shares of Waters from $400.00 to $425.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Finally, Wells Fargo & Company increased their price target on shares of Waters from $355.00 to $370.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, Waters presently has an average rating of “Moderate Buy” and a consensus price target of $394.56.

Waters Stock Performance

NYSE:WAT opened at $356.82 on Wednesday. The firm’s fifty day simple moving average is $344.19 and its 200 day simple moving average is $347.65. The company has a current ratio of 1.79, a quick ratio of 1.13 and a debt-to-equity ratio of 0.32. Waters Corporation has a twelve month low of $275.05 and a twelve month high of $414.15. The firm has a market capitalization of $35.04 billion, a price-to-earnings ratio of 45.34, a PEG ratio of 2.17 and a beta of 1.21.

Waters (NYSE:WAT) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.31 by $0.39. The firm had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.20 billion. Waters had a return on equity of 15.60% and a net margin of 11.91%.The firm’s quarterly revenue was up 91.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.25 EPS. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. As a group, equities research analysts expect that Waters Corporation will post 14.51 earnings per share for the current fiscal year.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.